Cover Image
市場調查報告書

XOMA Corporation的產品平台分析

XOMA Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 243040
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
XOMA Corporation的產品平台分析 XOMA Corporation - Product Pipeline Review - 2016
出版日期: 2016年06月22日 內容資訊: 英文 41 Pages
簡介

XOMA Corporation,是進行抗體為基礎的治療藥的藥物研發、開發的生物醫藥品企業。作為他們的主要產品的gevokizumab,各種用於於發炎性疾病和其他疾病的治療。

本報告提供XOMA Corporation的產品開發平台的現狀及各開發階段比較分析、藥物簡介、開發平台的分析與最新趨勢、現在暫停中的計劃等資訊。

XOMA Corporation的基本資料

XOMA Corporation概要

  • 主要資訊
  • 企業資料

XOMA Corporation:R&D概要

  • 主要的治療範圍

XOMA Corporation:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

XOMA Corporation:開發中產品概況

  • 後期開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

XOMA Corporation:藥物簡介

  • gevokizumab
  • XOMA-3-AB
  • XOMA-358
  • 單株抗體
  • XMet-A
  • XMet-S

XOMA Corporation:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

XOMA Corporation:最近的開發平台趨勢

XOMA Corporation:暫停中的計劃

XOMA Corporation:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • efalizumab
  • gevokizumab

XOMA Corporation:企業發表

XOMA Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08073CDB

Summary

Global Markets Direct's, 'XOMA Corporation - Product Pipeline Review - 2016', provides an overview of the XOMA Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by XOMA Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of XOMA Corporation
  • The report provides overview of XOMA Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses XOMA Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features XOMA Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate XOMA Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for XOMA Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding XOMA Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • XOMA Corporation Snapshot
    • XOMA Corporation Overview
    • Key Information
    • Key Facts
  • XOMA Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • XOMA Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • XOMA Corporation - Pipeline Products Glance
    • XOMA Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • XOMA Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • XOMA Corporation - Drug Profiles
    • XOMA-213
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XOMA-358
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Undisclosed Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize Parathyroid Hormone 1 Receptor for Hyperparathyroidism and Malignancy Induced Hypercalcemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XMet-A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XOMA-129
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XOMA-3-BB
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Modulate GPCR
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • XOMA Corporation - Pipeline Analysis
    • XOMA Corporation - Pipeline Products by Target
    • XOMA Corporation - Pipeline Products by Route of Administration
    • XOMA Corporation - Pipeline Products by Molecule Type
    • XOMA Corporation - Pipeline Products by Mechanism of Action
  • XOMA Corporation - Recent Pipeline Updates
  • XOMA Corporation - Dormant Projects
  • XOMA Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • gevokizumab
  • XOMA Corporation - Company Statement
  • XOMA Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • XOMA Corporation, Key Information
  • XOMA Corporation, Key Facts
  • XOMA Corporation - Pipeline by Indication, 2016
  • XOMA Corporation - Pipeline by Stage of Development, 2016
  • XOMA Corporation - Monotherapy Products in Pipeline, 2016
  • XOMA Corporation - Out-Licensed Products in Pipeline, 2016
  • XOMA Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • XOMA Corporation - Phase II, 2016
  • XOMA Corporation - Phase I, 2016
  • XOMA Corporation - Preclinical, 2016
  • XOMA Corporation - Discovery, 2016
  • XOMA Corporation - Pipeline by Target, 2016
  • XOMA Corporation - Pipeline by Route of Administration, 2016
  • XOMA Corporation - Pipeline by Molecule Type, 2016
  • XOMA Corporation - Pipeline Products by Mechanism of Action, 2016
  • XOMA Corporation - Recent Pipeline Updates, 2016
  • XOMA Corporation - Dormant Developmental Projects,2016
  • XOMA Corporation - Discontinued Pipeline Products, 2016
  • XOMA Corporation, Subsidiaries

List of Figures

  • XOMA Corporation - Pipeline by Top 10 Indication, 2016
  • XOMA Corporation - Pipeline by Stage of Development, 2016
  • XOMA Corporation - Monotherapy Products in Pipeline, 2016
  • XOMA Corporation - Out-Licensed Products in Pipeline, 2016
  • XOMA Corporation - Pipeline by Target, 2016
  • XOMA Corporation - Pipeline by Route of Administration, 2016
  • XOMA Corporation - Pipeline by Molecule Type, 2016
  • XOMA Corporation - Pipeline Products by Mechanism of Action, 2016
Back to Top